It is intriguing to observe that our MET gain-of-function approach documents glucose intolerance and hepatic insulin resistance, which have been previously reported in a mouse model conceived to work as a MET loss-of-function, based on the expression of an extracellular portion of MET in the liver (AlbDN-Met) [20,51]. This evidence concerns the gene MET and Insulin resistance.